Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2025 06:35 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire...
August 05, 2025 08:30 ET | Source: Y-mAbs Therapeutics, Inc.

SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

Acquisition to Include DANYELZA® (Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product PortfolioTransaction Expands SERB’s Investment in the U.S.SERB to Commence All-Cash Tender Offer to...
May 26, 2025 10:00 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
March 04, 2025 06:35 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
June 11, 2024 02:00 ET | Source: Essential Pharma

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma Egham, UK and Copenhagen,...
May 21, 2024 08:00 ET | Source: Bionano Genomics

Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy

Optical genome mapping was used in three publications to successfully assess genome integrity in stem cells, CAR-T cells, and iPSCs.
April 09, 2024 02:00 ET | Source: Essential Pharma

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma...
August 01, 2023 07:00 ET | Source: Renaissance Pharma

Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma

Press Release Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma ...
August 01, 2023 03:00 ET | Source: Renaissance Pharma

Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma

Press Release Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma ...
April 20, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Neuroblastoma Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Y-mabs therapeutics, Clarity Pharmaceuticals, K C Pharmaceuticals, Exelixis, Eli Lilly and Company, Innervate Radiopharmaceuticals, and Others Expected to Pr

New York, USA, April 20, 2023 (GLOBE NEWSWIRE) -- Neuroblastoma Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Y-mabs therapeutics, Clarity Pharmaceuticals, K C...